

press release

## OTOFARMA: A STRONG GAIN ON ITS FIRST TRADING DAY ON ITS DEBUT ON EURONEXT GROWTH MILAN

### 2025 FINANCIAL CALENDAR

Naples, August 6, 2025 – Otofarma Group – with over 30 years of experience in the hearing care sector and a leading manufacturer of hearing aids mainly distributed through the pharmacy channel – announces that today marks the start of trading of Otofarma S.p.A. ordinary shares on the Euronext Growth Milan (EGM) market.

The shares closed today's session at a price of €6.10, up 13% compared to the offering price of €5.40. At the end of the session, Otofarma's market capitalization exceeded €35 million.

*"We are extremely proud of the strong performance of our shares on their first day of trading," said **Gennaro Bartolomucci, Chairman of the Group**. "Listing on the EGM represents a key strategic step aimed at raising resources that will support and accelerate our future growth. We aim to consolidate our leadership position, enhance investments in technological innovation and patient services, and expand our presence across the territory through our network of pharmacies, thereby strengthening our competitive edge. A heartfelt thanks goes to everyone who supported us throughout this important and demanding journey that has brought us to this moment, which we see as a new starting point."*

*"Today we celebrate a milestone born of commitment, vision, and passion. Going public is not only a recognition of Otofarma's value, but also the beginning of a new chapter for the Group," stated **Giovanna Incarnato Bartolomucci, CEO of Otofarma**. "The market's positive response reinforces our determination to continue investing in research, innovation, and service quality, with the goal of improving the lives of people with hearing difficulties every day. We look to the future with enthusiasm, fully aware of both the responsibilities and opportunities that this new chapter brings."*

As part of the listing process on EGM, Otofarma was supported by Alantra Capital Markets as Euronext Growth Advisor, Global Coordinator, and Bookrunner; Broletto Corporate Advisory as Financial Advisor; ADVANT Nctm as Deal Legal Counsel; RSM Società di Revisione e Organizzazione Contabile S.p.A. as Auditor & Financial Due Diligence Advisor; and FIRST Tax and Legal for Tax Due Diligence.

The Admission Document is available at the Company's registered office and in the Investor Relations section of the website [www.otofarmaspa.com](http://www.otofarmaspa.com).

### 2025 Corporate Calendar

The Company announces the following upcoming event in the 2025 financial calendar, as approved by the Board of Directors on July 30, 2025:

- September 30, 2025: Board of Directors' meeting to approve the half-year financial report as of June 30, 2025

Any changes to the above date will be promptly communicated to the market by the Company.

\*\*\*\*\*

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by [CONSOB](#) by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998.

#### **Identification Codes**

- Alphanumeric Code: OTO
- ISIN for Ordinary Shares: IT0005663361

\*\*\*

#### **About Otofarma SpA**

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

#### **For more information:**

##### **Otofarma S.p.A.- Investor relations**

Anna Incarnato Bartolomucci

E-mail: [anna.incarnato@otofarma.it](mailto:anna.incarnato@otofarma.it)

mob: +39 347 0506780

##### **Alantra – Euronext Growth Advisor**

E-mail: [ega@alantra.com](mailto:ega@alantra.com)

mob: +39 334 6267242

– Media Relations:

##### **SEC Newgate – Media Relations**

+39 02 624 999 1

Michele Bon – [michele.bon@secnewgate.it](mailto:michele.bon@secnewgate.it) – +39 338 693 3868

Francesca Brambilla – [francesca.brambilla@secnewgate.it](mailto:francesca.brambilla@secnewgate.it) – +39 338 627 2146